A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...
A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...
Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...
A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...
For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...
MS is a chronic, immune-mediated disease affecting the central nervous system, with no known cure and varying levels of impact on individuals. Over 20 FDA-approved disease-modifying therapies exist, ...
Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...
In a transformative study published in the journal Science Translational Medicine, an international team of researchers has made a significant breakthrough in the understanding and potential treatment ...
As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of ...
Frexalimab (Sanofi), a novel, investigational second-generation inhibitor of the CD40 ligand, significantly reduced disease activity in relapsing multiple sclerosis (MS) and was well tolerated in a ...
A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study, MS treatment ...
The Marburg variant of multiple sclerosis is extremely rare but also the most severe. Life expectancy has been weeks or months, but advances in treatment have led to an improved outlook. Multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results